Toru Kumagai

Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial

Kazuhiko Nakagawa, Edward B. Garon, Takashi Seto et al. · The Lancet Oncology · 2019 · 613 citations · Full text

Medicine, Oncology, Pharmacology +12

Quantitative Detection of <i>EGFR</i> Mutations in Circulating Tumor DNA Derived from Lung Adenocarcinomas

Kazuya Taniguchi, Junji Uchida, Kazumi Nishino et al. · Clinical Cancer Research · 2011 · 318 citations

Medicine, Molecular Biology, Oncology +17

Tetraspanins CD9 and CD81 function to prevent the fusion of mononuclear phagocytes

Yoshito Takeda, Isao Tachibana, Kenji Miyado et al. · The Journal of Cell Biology · 2003 · 197 citations · Full text

Life Sciences, Cell Biology, Immunology +10

YAP modifies cancer cell sensitivity to EGFR and survivin inhibitors and is negatively regulated by the non-receptor type protein tyrosine phosphatase 14

J-M Huang, Izumi Nagatomo, Emi Suzuki et al. · Oncogene · 2012 · 151 citations

Life Sciences, Molecular Biology, Oncology +12

Final progression-free survival results from the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer

Kazuhiko Nakagawa, Toyoaki Hida, Hiroshi Nokihara et al. · Lung Cancer · 2019 · 147 citations

Medicine, Oncology, Pharmacology +16